Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1549-1554

  Drucker, Liat ^a   Stackievicz, Rodica ^a   Radnay, Judith ^a   Shapira, Hava ^a   Cohen, Ilan ^a   Yarkoni, Shai ^a  

^a MEIR MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; CDDP; Combined chemotherapy; Endometrium; Tamoxifen

Indexed keywords

CISPLATIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL POPULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIUM CELL; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TISSUE CULTURE CELL; TISSUE SPECIFICITY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CISPLATIN; DRUG SYNERGISM; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; STEROIDS; TAMOXIFEN;

EID: 0037900619     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17(1): 409-422, 1999.
2. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89(6): 1845-1853, 1997.
3. Walker EM Jr and Walker SM: Evolution of chemotherapy with platinum compounds. Ann Clin Lab Sci 29(4): 263-74, 1999.
4. Persons DL, Yazlovitskaya EM, Cui W and Pelling JC: Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5: 1007-1014, 1999.
5. Gosland M, Lum B, Schimmelpfennig J, Baker J and Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16(1): 16-39, 1996.
6. McClay EF, Albright KD, Jones JA, Christen RD and Howell SB: Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 55: 1018-1022, 1993.
7. McClay EF, Albright KD, Jones JA, Christen RD and Howell SB: Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 70(3): 449-452, 1994.
8. Cameron DA, Keen JC, Dixon JM, Bellamy C, Handy A and Miller WR: Effective tamoxifen therapy of breast cancer involves antiproliferative and pro-apoptotic changes. Eur J Cancer 36: 845-851, 2000.
9. Stackievicz R, Drucker L, Radnay J, Beith Y, Cohen I and Yarkoni S: Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures. Clin Can Res 7: 415-420, 2001.
10. McClay EF, Jones JA, Winski PJ, Albright KD, Christen RD and Howell SB: Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res 56(17): 3993-7, 1996.
11. McClay EF and Jones JA: Characterization of a human cell line with non-oestrogen receptor dependent tamoxifen resistance. Melanoma Res 9(6): 531-537, 1999.
12. Pu YS, Hsieh TS, Tsai TC, Cheng AL, Hsieh CY, Su IJ and Lai MK: Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154(2 pt 1): 601-605, 1995.
13. Nakata B, Albright KD, Barton RM, Howell SB and Los G: Synergistic interaction between cisplatin and tamoxifen delays the emergence of resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 35(6): 511-518, 1995.
14. Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF and Yang PC: High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable non-small cell lung carcinoma. Cancer 86(3): 415-420, 1999.
15. Fabian C, Sternson L and Barnett M: Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treatment Rep 64(6-7): 765-773, 1980.
16. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29(5): 658-664, 1981.
17. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 270-280, 1990.
18. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P and Macho A: Bcl-2 and Bcl-X antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62-67, 1997.
19. Lee SI, Brown MK and Eastman A: Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 58: 1713-1721, 1999.
20. Giorda G, Franceschi L, Crivellari D, Magri MD, Veronsei A, Scarabelli C and Furlanut M: Determination of tamoxifen and its metabolites in the endometrial tissue of long term treated women. Eur J Cancer 36 suppl 4: 88-89, 2000.
21. Shibutani S, Reardon JT, Suzuki N and Sancar A: Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res 60(10): 2607-2610, 2000.
22. Terashima I, Suzuki N and Shibutani S: Mutagenic potential of α-(N2-deoxyguanosinyl) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091-2095, 1999.
23. Delmastro DA, Li J, Vaisman A, Solle M and Chaney SG: DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39(3): 245-253, 1997.
24. Siddik ZH, Mims B, Lozano G and Thai G: Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58(4): 698-703, 1998.
25. Olson SH, Finstad CL, Harlap S, Kurian L, Saigo PE and Barakat RR: A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer. Cancer Epidemiol Biomarkers Prev 6(10): 815-7, 1997.
26. Kuwashima Y, Kurosumi M, kobayashi Y, Tanuma J, Suemasu K, Higashi Y, Kasamatsu T, Shiromizu K and Kishi K: Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int J Gynecol Pathol 17(2): 135-139, 1998.
27. Emons G, Fleckenstein G, Hinney B, Huschmand A and Heyl W: Hormonal interactions in endometrial cancer. Endocrine-Related Cancer 7: 227-242, 2000.
28. Roth JA, Swisher SG and Meyn RE: P53 tumor suppressor gene therapy for cancer. Oncology 13(10 suppl 5): 48-54, 1999.
29. Song K, Li Z, Seth P, Cowan KH and Sinha BK: Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 in human ovarian carcinomas. Oncol Res 9(11-12): 603-609, 1997.
30. Te-Hsiu L, Lea-Yea C and Wen-Chun H: Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 18: 4269-4274, 1999.
31. Lincet H, Poulain L, Remy Js, Deslandes E, Duigou F, Gauduchon P and Staedel C: The p21 (cip1/waf1) cyclin-dependent kinase inhibitor enhances the-cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 161(1): 17-26, 2000.
32. Oshita F, Kameda Y, Nishio K, Tanaka G, Yamada K, Nomura I, Nakayama H and Noda K: Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep 7(3): 491-495, 2000.
33. Funaoka K, Shindoh M, Yamashita T, Fujinaga K, Amemiya A and Totsuka Y: High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1/Cip1 level. Cancer Lett 108(1): 15-23, 1996.
34. Shiozawa T, Nikaido T, Nakayama K, Lu X and Fujii S: Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and hyperplastic endometrium treated with progesterone. Mol Hum Reprod 4(9): 899-905, 1998.
35. Bamberger CM, Thuneke I, Erdmann I, Schulte HM and Loning T: Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Vichows Arch 434(5): 423-428, 1999.
36. Toki T, Mori A, Shimizu M, Nikaido T and Fujii S: Localization of apoptotic cells within the human endometrium and correlation between apoptosis and p21 expression. Mol Hum Reprod 4(12): 1157-1164, 1998.